KR102408161B1 - 대상체가 췌관 선암을 앓을 위험을 평가하기 위한 초기 및 비 침습적 방법 및 이러한 질환의 치료 방법 - Google Patents

대상체가 췌관 선암을 앓을 위험을 평가하기 위한 초기 및 비 침습적 방법 및 이러한 질환의 치료 방법 Download PDF

Info

Publication number
KR102408161B1
KR102408161B1 KR1020217014527A KR20217014527A KR102408161B1 KR 102408161 B1 KR102408161 B1 KR 102408161B1 KR 1020217014527 A KR1020217014527 A KR 1020217014527A KR 20217014527 A KR20217014527 A KR 20217014527A KR 102408161 B1 KR102408161 B1 KR 102408161B1
Authority
KR
South Korea
Prior art keywords
βig
antibody
antagonist
pdac
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217014527A
Other languages
English (en)
Korean (ko)
Other versions
KR20210059020A (ko
Inventor
김인산
삘립 베르또리노
안나 엥니노
Original Assignee
엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름)
쌩뜨레 나티오날 데 라 르세르쉬 생띠끄
위니베르시테 끌로드 베르나르 리옹 Ⅰ
상뜨로 레옹 베라르
한국과학기술연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름), 쌩뜨레 나티오날 데 라 르세르쉬 생띠끄, 위니베르시테 끌로드 베르나르 리옹 Ⅰ, 상뜨로 레옹 베라르, 한국과학기술연구원 filed Critical 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름)
Publication of KR20210059020A publication Critical patent/KR20210059020A/ko
Application granted granted Critical
Publication of KR102408161B1 publication Critical patent/KR102408161B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G01N33/57438—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G01N33/57488—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217014527A 2016-03-15 2017-03-15 대상체가 췌관 선암을 앓을 위험을 평가하기 위한 초기 및 비 침습적 방법 및 이러한 질환의 치료 방법 Active KR102408161B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16305276.4 2016-03-15
EP16305276 2016-03-15
KR1020187027907A KR102402444B1 (ko) 2016-03-15 2017-03-15 대상체가 췌관 선암을 앓을 위험을 평가하기 위한 초기 및 비 침습적 방법 및 이러한 질환의 치료 방법
PCT/EP2017/056150 WO2017158043A1 (en) 2016-03-15 2017-03-15 Early and non invasive method for assessing a subject's risk of having pancreatic ductal adenocarcinoma and methods of treatement of such disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187027907A Division KR102402444B1 (ko) 2016-03-15 2017-03-15 대상체가 췌관 선암을 앓을 위험을 평가하기 위한 초기 및 비 침습적 방법 및 이러한 질환의 치료 방법

Publications (2)

Publication Number Publication Date
KR20210059020A KR20210059020A (ko) 2021-05-24
KR102408161B1 true KR102408161B1 (ko) 2022-06-13

Family

ID=55588194

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217014527A Active KR102408161B1 (ko) 2016-03-15 2017-03-15 대상체가 췌관 선암을 앓을 위험을 평가하기 위한 초기 및 비 침습적 방법 및 이러한 질환의 치료 방법
KR1020187027907A Active KR102402444B1 (ko) 2016-03-15 2017-03-15 대상체가 췌관 선암을 앓을 위험을 평가하기 위한 초기 및 비 침습적 방법 및 이러한 질환의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187027907A Active KR102402444B1 (ko) 2016-03-15 2017-03-15 대상체가 췌관 선암을 앓을 위험을 평가하기 위한 초기 및 비 침습적 방법 및 이러한 질환의 치료 방법

Country Status (10)

Country Link
US (2) US11740243B2 (enExample)
EP (2) EP3430404B1 (enExample)
JP (3) JP6903680B2 (enExample)
KR (2) KR102408161B1 (enExample)
DK (2) DK3779447T3 (enExample)
ES (2) ES2911038T3 (enExample)
FI (1) FI3779447T3 (enExample)
HR (2) HRP20220335T1 (enExample)
PL (2) PL3430404T3 (enExample)
WO (1) WO2017158043A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2911038T3 (es) * 2016-03-15 2022-05-17 Inst Nat Sante Rech Med Procedimiento temprano y no invasivo para evaluar el riesgo de un sujeto de tener adenocarcinoma ductal pancreático y procedimientos de tratamiento de dicha enfermedad
US20210340240A1 (en) * 2018-10-18 2021-11-04 INSERM (Institut National de la Santé et de la Recherche Médicale Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
KR102169346B1 (ko) * 2019-03-27 2020-10-23 덕성여자대학교 산학협력단 이종이식 동물 모델의 제조방법 및 이종이식 성공 여부 판별 방법
US20240368260A1 (en) 2021-07-29 2024-11-07 Institut National De La Sante Et De La Recherche Medicale HUMANIZED ANTI-HUMAN ßIG-H3 PROTEIN AND USES THEREOF
WO2025068157A1 (en) * 2023-09-25 2025-04-03 Stromacare COMBINATION OF A βIG-H3 ANTAGONIST AND A PDFG-AA ANTAGONIST FOR THE TREATMENT OF CANCER
WO2025224297A1 (en) * 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092729A2 (en) 2005-03-04 2006-09-08 Consorzio Per Gli Studi Universitari In Verona Novel biomarkers for diagnosis and/or prognosis or prognosis of neoplasias in animals
WO2012079977A1 (en) * 2010-12-13 2012-06-21 Universite De Liege Biomarkers, uses of biomarkers and a method of identifying biomarkers
WO2014113406A1 (en) 2013-01-15 2014-07-24 Fred Hutchinson Cancer Research Center Compositions and methods for treating pancreatic cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
WO2001068836A2 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
EP1502114A4 (en) * 2002-04-19 2006-06-07 Regen Biotech Inc METHOD FOR MEASURING THE PROTEIN AMOUNT $ G (B) IG-H3 AND DIAGNOSTIC KIT USING THE SAME
KR20060056445A (ko) 2004-11-19 2006-05-24 주식회사 리젠 바이오텍 인간 βｉｇ－ｈ３에 대한 단클론 항체
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
KR101515700B1 (ko) 2013-05-15 2015-04-27 경북대학교 산학협력단 Tgfbi를 이용한 패혈증 진단용 조성물 및 이를 이용한 패혈증 예방 또는 치료용 약학적 조성물과 이의 스크리닝 방법
WO2015200790A2 (en) 2014-06-26 2015-12-30 Yale University Compositions and methods to regulate renalase in the treatment of diseases and disorders
CN116327915A (zh) 2015-04-03 2023-06-27 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
ES2911038T3 (es) * 2016-03-15 2022-05-17 Inst Nat Sante Rech Med Procedimiento temprano y no invasivo para evaluar el riesgo de un sujeto de tener adenocarcinoma ductal pancreático y procedimientos de tratamiento de dicha enfermedad
KR102082344B1 (ko) * 2018-06-21 2020-02-27 조성은 담도암의 진단 또는 예후 예측용 바이오마커 및 이의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092729A2 (en) 2005-03-04 2006-09-08 Consorzio Per Gli Studi Universitari In Verona Novel biomarkers for diagnosis and/or prognosis or prognosis of neoplasias in animals
WO2012079977A1 (en) * 2010-12-13 2012-06-21 Universite De Liege Biomarkers, uses of biomarkers and a method of identifying biomarkers
WO2014113406A1 (en) 2013-01-15 2014-07-24 Fred Hutchinson Cancer Research Center Compositions and methods for treating pancreatic cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Andrei Turtoi et al, Journal of Proteome Research (2011), vol 10, no 9, pp 4302-4313.
Maeva Patry et al, Diabetes (2015), vol 64, pp 4212-4219.
Ya Ting Chang et al, PLOS ONE (2011), vol 6, no 5, pp e20029, XP055036528, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0020029.

Also Published As

Publication number Publication date
EP3430404A1 (en) 2019-01-23
US20240159759A1 (en) 2024-05-16
PL3779447T3 (pl) 2023-06-26
KR102402444B1 (ko) 2022-05-27
US20190086417A1 (en) 2019-03-21
HRP20220335T1 (hr) 2022-05-13
EP3779447A1 (en) 2021-02-17
ES2911038T3 (es) 2022-05-17
JP6903680B2 (ja) 2021-07-14
US11740243B2 (en) 2023-08-29
KR20210059020A (ko) 2021-05-24
EP3430404B1 (en) 2022-01-05
PL3430404T3 (pl) 2022-05-02
WO2017158043A1 (en) 2017-09-21
DK3430404T3 (da) 2022-03-21
JP2023052360A (ja) 2023-04-11
DK3779447T3 (da) 2023-04-24
JP2019512695A (ja) 2019-05-16
HRP20230391T1 (hr) 2023-07-07
JP7569741B2 (ja) 2024-10-18
EP3779447B1 (en) 2023-02-08
US12140594B2 (en) 2024-11-12
ES2944259T3 (es) 2023-06-20
FI3779447T3 (fi) 2023-04-21
JP2021119146A (ja) 2021-08-12
KR20180120716A (ko) 2018-11-06

Similar Documents

Publication Publication Date Title
JP7569741B2 (ja) 膵管腺ガンを有する被験体のリスクを評価するための早期かつ非侵襲的な方法及びこのような疾患の処置方法
CN112703012A (zh) 治疗癌症的方法
EP3293271A1 (en) Marker and target as a diagnostic variable and target for therapy of metastatic cancer
US20210340240A1 (en) Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
US20190271702A1 (en) Methods of treatement of cancer disease by targetting tumor associated macrophage
WO2014167529A1 (en) Methods and compositions for preventing and treating atherosclerosis
KR20210126057A (ko) 암세포에 존재하는 케라틴 14(krt14)의 세포외 부분을 표적화함으로써 암을 치료하거나 예방하는 방법
JP2020143122A (ja) Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用
US20200088732A1 (en) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
JP2022068145A (ja) Ｆｚｄ１０に対するモノクローナル抗体およびその使用
JP2011520781A (ja) 治療、診断及び検査のためのｍｓ４ａ１２を伴う方法、及びｍｓ４ａ１２を標的とする剤
WO2021030450A9 (en) Novel lox-1 antibody compositions, lox1 neutralization assay and methods of treatment using same
CA3250546A1 (en) IL7R MODULATOR ACTIVITY BIOMARKERS
KR20170138465A (ko) Igf-1r 항체 및 암의 진단을 위한 그의 용도
US20150377888A1 (en) Methods for Predicting and Preventing Metastasis in Triple Negative Breast Cancers
CN116940844A (zh) 新颖生物标志物及其用途

Legal Events

Date Code Title Description
A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000